4506 ORAL A large open-label, non-comparative, phase III study of the multi-targeted kinase inhibitor sorafenib in European patients with advanced renal cell carcinoma
Beck, J., Bajetta, E., Escudier, B., Negrier, S., Keilholz, U., Szczylik, C., Mersmann, S., Burock, K., Erlandsson, F., Huber, C.Том:
5
Мова:
english
Журнал:
European Journal of Cancer Supplements
DOI:
10.1016/S1359-6349(07)71137-0
Date:
September, 2007
Файл:
PDF, 59 KB
english, 2007